Goal directed fluid removal with furosemide versus placebo in intensive care patients with fluid overload: A trial protocol for a randomised, blinded trial (GODIF trial).


Journal

Acta anaesthesiologica Scandinavica
ISSN: 1399-6576
Titre abrégé: Acta Anaesthesiol Scand
Pays: England
ID NLM: 0370270

Informations de publication

Date de publication:
10 2022
Historique:
received: 14 06 2022
accepted: 03 07 2022
pubmed: 29 7 2022
medline: 20 9 2022
entrez: 28 7 2022
Statut: ppublish

Résumé

Fluid overload is a risk factor for mortality in intensive care unit (ICU) patients. Administration of loop diuretics is the predominant treatment of fluid overload, but evidence for its benefit is very uncertain when assessed in a systematic review of randomised clinical trials. The GODIF trial will assess the benefits and harms of goal directed fluid removal with furosemide versus placebo in ICU patients with fluid overload. An investigator-initiated, international, randomised, stratified, blinded, parallel-group trial allocating 1000 adult ICU patients with fluid overload to infusion of furosemide versus placebo. The goal is to achieve a neutral fluid balance. The primary outcome is days alive and out of hospital 90 days after randomisation. Secondary outcomes are all-cause mortality at day 90 and 1-year after randomisation; days alive at day 90 without life support; number of participants with one or more serious adverse events or reactions; health-related quality of life and cognitive function at 1-year follow-up. A sample size of 1000 participants is required to detect an improvement of 8% in days alive and out of hospital 90 days after randomisation with a power of 90% and a risk of type 1 error of 5%. The conclusion of the trial will be based on the point estimate and 95% confidence interval; dichotomisation will not be used. gov identifier: NCT04180397. The GODIF trial will provide important evidence of possible benefits and harms of fluid removal with furosemide in adult ICU patients with fluid overload.

Sections du résumé

BACKGROUND
Fluid overload is a risk factor for mortality in intensive care unit (ICU) patients. Administration of loop diuretics is the predominant treatment of fluid overload, but evidence for its benefit is very uncertain when assessed in a systematic review of randomised clinical trials. The GODIF trial will assess the benefits and harms of goal directed fluid removal with furosemide versus placebo in ICU patients with fluid overload.
METHODS
An investigator-initiated, international, randomised, stratified, blinded, parallel-group trial allocating 1000 adult ICU patients with fluid overload to infusion of furosemide versus placebo. The goal is to achieve a neutral fluid balance. The primary outcome is days alive and out of hospital 90 days after randomisation. Secondary outcomes are all-cause mortality at day 90 and 1-year after randomisation; days alive at day 90 without life support; number of participants with one or more serious adverse events or reactions; health-related quality of life and cognitive function at 1-year follow-up. A sample size of 1000 participants is required to detect an improvement of 8% in days alive and out of hospital 90 days after randomisation with a power of 90% and a risk of type 1 error of 5%. The conclusion of the trial will be based on the point estimate and 95% confidence interval; dichotomisation will not be used.
CLINICALTRIALS
gov identifier: NCT04180397.
PERSPECTIVE
The GODIF trial will provide important evidence of possible benefits and harms of fluid removal with furosemide in adult ICU patients with fluid overload.

Identifiants

pubmed: 35898170
doi: 10.1111/aas.14121
pmc: PMC9541596
doi:

Substances chimiques

Sodium Potassium Chloride Symporter Inhibitors 0
Furosemide 7LXU5N7ZO5

Banques de données

ClinicalTrials.gov
['NCT04180397']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1138-1145

Informations de copyright

© 2022 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

Références

Acta Anaesthesiol Scand. 2019 Oct;63(9):1184-1190
pubmed: 31282567
BMJ Open. 2020 Dec 28;10(12):e039875
pubmed: 33372073
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Acute Crit Care. 2020 Aug;35(3):189-196
pubmed: 32811137
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
J Anesth. 2019 Jun;33(3):354-363
pubmed: 30919134
PLoS One. 2019 May 31;14(5):e0217911
pubmed: 31150512
N Engl J Med. 2006 Jun 15;354(24):2564-75
pubmed: 16714767
J Crit Care. 2015 Aug;30(4):860.e7-13
pubmed: 25979272
Crit Care. 2015 Jun 15;19:251
pubmed: 26073560
BMC Nephrol. 2017 Feb 1;18(1):45
pubmed: 28143505
Alzheimers Dement (Amst). 2021 Feb 05;13(1):e12144
pubmed: 33598528
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Intensive Care Med. 2022 Feb;48(2):190-200
pubmed: 34913089
Lancet Neurol. 2021 Aug;20(8):627-638
pubmed: 34302787
Crit Care Med. 2020 Dec;48(12):1862-1870
pubmed: 33009098
Intensive Care Med. 2001 Dec;27(12):1901-7
pubmed: 11797026
Anaesthesiol Intensive Ther. 2014 Nov-Dec;46(5):361-80
pubmed: 25432556
Intensive Care Med. 2011 May;37(5):801-7
pubmed: 21373821
Intensive Care Med. 2018 Jul;44(7):1081-1089
pubmed: 29767323
Crit Care. 2016 Jun 23;20(1):196
pubmed: 27334608
Intensive Care Med. 2018 Apr;44(4):409-417
pubmed: 29589054
J Intensive Care Soc. 2020 May;21(2):111-118
pubmed: 32489406
Ann Intensive Care. 2022 Jun 13;12(1):52
pubmed: 35696008
Nat Rev Nephrol. 2010 Feb;6(2):107-15
pubmed: 20027192
Crit Care Med. 2019 Sep;47(9):e753-e760
pubmed: 31162196
Crit Care Med. 2016 Oct;44(10):1891-900
pubmed: 27352125
Acta Anaesthesiol Scand. 2018 Jul;62(6):780-790
pubmed: 29512107
Crit Care. 2020 Feb 28;24(1):70
pubmed: 32111247
Shock. 2015 Jan;43(1):68-73
pubmed: 25247784
N Engl J Med. 2018 Dec 6;379(23):2199-2208
pubmed: 30354950
Acta Anaesthesiol Scand. 2022 Oct;66(9):1138-1145
pubmed: 35898170
Acta Anaesthesiol Scand. 2019 Oct;63(9):1216-1224
pubmed: 31273763
JAMA. 2013 Oct 16;310(15):1591-600
pubmed: 24108501
Crit Care. 2015 Oct 23;19:371
pubmed: 26494153
Clin J Am Soc Nephrol. 2011 May;6(5):966-73
pubmed: 21393482
Crit Care Med. 2004 Aug;32(8):1669-77
pubmed: 15286542

Auteurs

Sine Wichmann (S)

Department of Anaesthesiology, Copenhagen University Hospital - North Zealand, Hilleroed, Denmark.

Theis S Itenov (TS)

Department of Anaesthesiology, Copenhagen University Hospital - North Zealand, Hilleroed, Denmark.

Rasmus E Berthelsen (RE)

Department of Anaesthesiology, Copenhagen University Hospital - North Zealand, Hilleroed, Denmark.

Theis Lange (T)

Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Anders Perner (A)

Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Christian Gluud (C)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Pia Lawson-Smith (P)

Department of Intensive Care, Odense University Hospital, Odense, Denmark.

Lars Nebrich (L)

Department of Anaesthesia and Intensive Care, Zealand University Hospital, Koege, Denmark.

Jørgen Wiis (J)

Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Anne C Brøchner (AC)

Department of Anaesthesia and Intensive Care, University Hospital of Southern Denmark, Kolding, Denmark.

Thomas Hildebrandt (T)

Department of Anaesthesia and Intensive Care, Zealand University Hospital, Roskilde, Denmark.

Meike T Behzadi (MT)

Department of Intensive Care, Aalborg University Hospital, Aalborg, Denmark.

Kristian Strand (K)

Department of Intensive Care, Stavanger University Hospital, Stavanger, Norway.

Finn H Andersen (FH)

Department of Intensive Care, Ålesund Hospital, Møre and Romsdal Health Trust, Ålesund, Norway.
Department of Circulation and Medical Imaging, Faculty of Medicine and Health Science, Norwegian University of Science and Technology, Trondheim, Norway.

Thomas Strøm (T)

Department of Anaesthesia and Intensive Care, Sygehus Sønderjylland, Aabenraa, Denmark.

Mikko Järvisalo (M)

Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland.

Kjeld A J Damgaard (KAJ)

Department of Anaesthesia and Intensive Care, Regions Hospital Nordjylland, Hjørring, Denmark.

Marianne L Vang (ML)

Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark.

Rebecka R Wahlin (RR)

Department of Anaesthesia and Intensive Care, Södersjukhuset AB, Stockholm, Sweden.

Martin I Sigurdsson (MI)

Department of Anaesthesia and Intensive Care, Landspitali, Reykjavik, Iceland.
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Katrin M Thormar (KM)

Department of Anaesthesia and Intensive Care, Landspitali, Reykjavik, Iceland.

Marlies Ostermann (M)

Department of Intensive Care, King's College London, Guy's & St. Thomas' Foundation Trust, London, UK.

Frederik Keus (F)

Department of Critical Care, University Medical Centre Groningen, Groningen, The Netherlands.

Morten H Bestle (MH)

Department of Anaesthesiology, Copenhagen University Hospital - North Zealand, Hilleroed, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH